help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on December 10, 2004, doi:10.1164/rccm.200406-729OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200406-729OCv1
171/6/606    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fessler, M. B.
Right arrow Articles by Worthen, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fessler, M. B.
Right arrow Articles by Worthen, G. S.
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 606-615, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200406-729OC


Original Article

A Role for Hydroxy-Methylglutaryl Coenzyme A Reductase in Pulmonary Inflammation and Host Defense

Michael B. Fessler, Scott K. Young, Samithamby Jeyaseelan, Jonathan G. Lieber, Patrick G. Arndt, Jerry A. Nick and G. Scott Worthen

Department of Medicine, National Jewish Medical and Research Center; and Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado

Correspondence and requests for reprints should be addressed to Michael B. Fessler, M.D., Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, D403 Neustadt, Denver, CO 80206. E-mail: michael.fessler{at}uchsc.edu

Rationale: A growing literature indicates that hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) modulate proinflammatory cellular signaling and functions. No studies to date, however, have addressed whether statins modulate pulmonary inflammation triggered by aerogenic stimuli or whether they affect host defense. Objectives: To test whether lovastatin modulates LPS-induced pulmonary inflammation and antibacterial host defense. Methods: To address these questions, and to confirm any effect of statins as dependent on inhibition of hydroxy-methylglutaryl coenzyme A reductase, we treated C57Bl/6 mice with three oral doses of 10 mg/kg lovastatin (or vehicle) and three intraperitoneal doses of 10 mg/kg mevalonic acid (or saline), and then exposed them to the following: (1) aerosolized LPS, (2) intratracheal keratinocyte-derived chemokine (KC), or (3) intratracheal Klebsiella pneumoniae. Measurements and main results: LPS- and KC-induced airspace neutrophils were reduced by lovastatin, an effect that was blocked by mevalonic acid cotreatment. Lovastatin was also associated with reduced parenchymal myeloperoxidase and microvascular permeability, and altered airspace and serum cytokines after LPS. Native pulmonary clearance of K. pneumoniae was inhibited by lovastatin and extrapulmonary dissemination was enhanced, both reversibly with mevalonic acid. Ex vivo studies of neutrophils isolated from lovastatin-treated mice confirmed inhibitory effects on Rac activation, actin polymerization, chemotaxis, and bacterial killing. Conclusion: Lovastatin attenuates pulmonary inflammation induced by aerosolized LPS and impairs host defense.

Key Words: acute respiratory distress syndrome • lipopolysaccharide • pneumonia • rho • statins




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W. Chen, S. Pendyala, V. Natarajan, J. G. N. Garcia, and J. R. Jacobson
Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition
Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L575 - L583.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Smoak, J. Madenspacher, S. Jeyaseelan, B. Williams, D. Dixon, K. R. Poch, J. A. Nick, G. S. Worthen, and M. B. Fessler
Effects of Liver X Receptor Agonist Treatment on Pulmonary Inflammation and Host Defense
J. Immunol., March 1, 2008; 180(5): 3305 - 3312.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Baldan, A. V. Gomes, P. Ping, and P. A. Edwards
Loss of ABCG1 Results in Chronic Pulmonary Inflammation
J. Immunol., March 1, 2008; 180(5): 3560 - 3568.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. E. Alexeeff, A. A. Litonjua, D. Sparrow, P. S. Vokonas, and J. Schwartz
Statin Use Reduces Decline in Lung Function: VA Normative Aging Study
Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 742 - 747.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. B. J. Mancini
Clarion Call for Trials Assessing "Cardiopulmonary" Agents To Reduce Morbidity and Mortality in Inflammatory Lung Diseases
Chest, April 1, 2007; 131(4): 950 - 951.
[Full Text] [PDF]


Home page
ChestHome page
F. J. Frost, H. Petersen, K. Tollestrup, and B. Skipper
Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins
Chest, April 1, 2007; 131(4): 1006 - 1012.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Jeyaseelan, S. K. Young, M. B. Fessler, Y. Liu, K. C. Malcolm, M. Yamamoto, S. Akira, and G. S. Worthen
Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-beta (TRIF)-Mediated Signaling Contributes to Innate Immune Responses in the Lung during Escherichia coli Pneumonia
J. Immunol., March 1, 2007; 178(5): 3153 - 3160.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. B. Fessler, P. G. Arndt, I. Just, J. A. Nick, K. C. Malcolm, and G. Scott Worthen
Dual role for RhoA in suppression and induction of cytokines in the human neutrophil
Blood, February 1, 2007; 109(3): 1248 - 1256.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. G. Arndt, S. K. Young, K. R. Poch, J. A. Nick, S. Falk, R. W. Schrier, and G. S. Worthen
Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways
J. Immunol., November 15, 2006; 177(10): 7233 - 7241.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
E M W van de Garde, E Hak, P C Souverein, A W Hoes, J M M van den Bosch, and H G M Leufkens
Statin treatment and reduced risk of pneumonia in patients with diabetes
Thorax, November 1, 2006; 61(11): 957 - 961.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
P. M. Henson, G. P. Cosgrove, and R. W. Vandivier
State of the Art. Apoptosis and Cell Homeostasis in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, August 1, 2006; 3(6): 512 - 516.
[Full Text] [PDF]


Home page
ThoraxHome page
E Hothersall, C McSharry, and N C Thomson
Potential therapeutic role for statins in respiratory disease.
Thorax, August 1, 2006; 61(8): 729 - 734.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Jeyaseelan, S. K. Young, M. Yamamoto, P. G. Arndt, S. Akira, J. K. Kolls, and G. S. Worthen
Toll/IL-1R Domain-Containing Adaptor Protein (TIRAP) Is a Critical Mediator of Antibacterial Defense in the Lung against Klebsiella pneumoniae but Not Pseudomonas aeruginosa
J. Immunol., July 1, 2006; 177(1): 538 - 547.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G.B. J. Mancini, M. Etminan, B. Zhang, L. E. Levesque, J. M. FitzGerald, and J. M. Brophy
Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2554 - 2560.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Morimoto, W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y.-Q. Xiao, J. A. Kench, P. M. Henson, and R. W. Vandivier
Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease.
J. Immunol., June 15, 2006; 176(12): 7657 - 7665.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. P. van de Visse, M. van der Heijden, J. Verheij, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, A. R. J. Girbes, and A. B. J. Groeneveld
Effect of prior statin therapy on capillary permeability in the lungs after cardiac or vascular surgery.
Eur. Respir. J., May 1, 2006; 27(5): 1026 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Nawrot, A. Nemmar, and B. Nemery
Update in environmental and occupational medicine 2005.
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 948 - 952.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
E. B. Milbrandt, A. Ishizaka, and D. C. Angus
Update in critical care 2005.
Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 833 - 841.
[Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Jeyaseelan, R. Manzer, S. K. Young, M. Yamamoto, S. Akira, R. J. Mason, and G. S. Worthen
Induction of CXCL5 During Inflammation in the Rodent Lung Involves Activation of Alveolar Epithelium
Am. J. Respir. Cell Mol. Biol., June 1, 2005; 32(6): 531 - 539.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society
  ATS Best of the Web